| Name | Title | Contact Details |
|---|
Velico Medical is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Veranda Of Columbus is a Columbus, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acusis is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Center of McKinney (MCM) is a growing 260-bed hospital with a 90-year history of serving the health care needs of McKinney and the surrounding communities. Over the past several years, MCM has strengthened its medical foundations by adding two new surgical robots, a newly remodeled labor and delivery suites, a Level III Neonatal Intensive Care Unit (NICU) and an advanced biplane Catheterization (cath) lab to treat heart rhythm disorders. Medical Center of McKinney will be expanding its services to the community with the addition of a new off-campus emergency department at 380 & Custer in 2015.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.